#United States #San Diego #Robbins LLP #Actinium Pharmaceuticals #Iomab-B

Legal Proceedings Emerge for ATNM Investors

Recent developments surrounding Actinium Pharmaceuticals, Inc. (NYSE: ATNM) have prompted significant attention among investors. A class action lawsuit has been initiated on behalf of shareholders who acquired securities of Actinium between October 31, 2022, and August 2, 2024. Robbins LLP, a law firm specializing in securities litigation, is leading the charge and has reminded affected shareholders of their rights and options.

Background on Actinium Pharmaceuticals

Actinium Pharmaceuticals is a biopharmaceutical entity focused on developing innovative cancer treatments using targeted radiotherapies, notably Iomab-B. This treatment is crucial for patients who have not responded to existing oncology therapies. The recent allegations against the company center on claims that it misrepresented the likelihood of FDA approval for Iomab-B.

The class action claims suggest that during the period in question, Actinium's management suggested there was a strong possibility that the FDA would approve the company's Biologics License Application (BLA) for Iomab-B. However, evidence presented in the lawsuit indicates that crucial data from the Sierra Trial—specifically related to Overall Survival rates—failed to meet significant clinical endpoints. These failures were allegedly downplayed by the company's representatives.

The Allegations

According to the suit, Actinium repeatedly highlighted the successful Disease Control Rate (DCR) from the Sierra Trial while minimizing the implications of the less favorable Overall Survival data. Furthermore, management purportedly assured investors that the FDA had endorsed the trial's design, implying that the observed deficiencies in survival data would not impede the approval process. This assertion has been critically challenged in the ongoing litigation.

Following an announcement on August 5, 2024, which stated that the FDA determined the Sierra trial findings were insufficient to support a BLA for Iomab-B, Actinium’s share price plummeted by approximately 60%, closing at $2.48. This dramatic drop has intensified investor scrutiny and raised important questions regarding the company's disclosures and statements made in previous communications.

Next Steps for Investors

Shareholders of Actinium who wish to participate as lead plaintiffs in the class action have a deadline to file their paperwork by May 26, 2025. Those interested should promptly contact Robbins LLP for assistance. It is noteworthy that participation in the case is not a prerequisite for any potential recovery; dissatisfied shareholders can remain absent class members.

Robbins LLP operates on a contingency fee basis, meaning that shareholders will incur no upfront costs or legal fees unless recovery is achieved. The firm has a long-standing history of advocating for shareholder rights and securing accountability from corporate executives. Their commitment to representation has established them as a reliable option for those seeking justice through legal means.

Conclusion

As this class action evolves, it serves as a critical reminder to shareholders about the importance of transparency and the implications of miscommunication within publicly traded companies. Investors are encouraged to stay informed and to utilize legal avenues available to address their grievances effectively. For more details or to initiate claims, affected individuals can reach out to Robbins LLP through provided contact options. The outcome of this case may have substantial repercussions not only for those directly involved but also for the future practices of Actinium Pharmaceuticals as they strive to maintain investor confidence and navigate the regulatory landscape of biopharmaceutical approvals.